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Abstract Abnormal synchronous activation of the gluta-
matergic olivo-cerebellar pathway has been suggested to be
crucial for the harmaline-induced tremor. The cerebellum
receives two catecholaminergic pathways: the dopaminer-
gic pathway arising from the ventral tegmental area/
substantia nigra pars compacta, and the noradrenergic one
from the locus coeruleus. The aim of the present study was
to examine a contribution of the cerebellar catecholaminer-
gic innervations to the harmaline-induced tremor in rats.
Rats were injected bilaterally into the cerebellar vermis
with 6-hydroxydopamine (6-OHDA; 8 μg/0.5 μl) either
alone or this treatment was preceded (30 min earlier) by
desipramine (15 mg/kg ip). Harmaline was administered to
animals in doses of 7.5 or 15 mg/kg ip. Tremor of forelimbs
was measured as a number of episodes during a 90-min
observation. Rats were killed by decapitation 30 or 120 min
after harmaline treatment. The levels of dopamine, nor-
adrenaline, serotonin, and their metabolites were measured
by HPLC in the cerebellum, substantia nigra, caudate–
putamen, and frontal cortex. 6-OHDA injected alone
enhanced the harmaline-induced tremor. Furthermore, it
decreased the noradrenaline level by ca. 40–80% in the
cerebellum and increased the levels of serotonin and 5-
HIAA in the caudate–putamen and frontal cortex in
untreated and/or harmaline-treated animals. When 6-
OHDA treatment was preceded by desipramine, it de-
creased dopaminergic transmission in some regions of the
cerebellum while inducing its compensatory activation in
others. The latter lesion did not markedly influence the
tremor induced by harmaline. The present study indicates
that noradrenergic innervation of the cerebellum interacts
with cerebral serotonergic systems and plays an inhibitory
role in the harmaline-induced tremor.
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Introduction
The cerebellum is generally accepted to be involved in
the control and integration of motor processes as well as
of cognitive functions. Several studies have suggested an
important role of this structure in pathological processes
underlying different forms of tremor, schizophrenia,
attention deficit, and Parkinson’s disease. Abnormal
activation of climbing glutamatergic fibers arising from
the inferior olive, which induces synchronous firing of
Purkinje cells of the cerebellar cortex has been assumed
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DOI 10.1007/s12311-011-0250-9to be a “pacemaker” responsible for development of
essential tremor [1]. Moreover, recent studies have
suggested some contribution of the cerebellum and its
efferent connections with the ventrolateral thalamus to
the tremor accompanying Parkinson’sd i s e a s e[ 2–9]. The
cerebellar cortex receives catecholaminergic innervations
that include a small dopaminergic pathway arising from
the ventral tegmental area/substantia nigra pars compacta,
and a heavy noradrenergic projection from the locus
coeruleus [10–14]. These regions are destroyed in the
course of Parkinson’sd i s e a s e[ 15]; however, a contribu-
tion of losses of dopaminergic and/or noradrenergic
cerebellar terminals to Parkinsonian tremor has not been
evaluated, so far. In contrast, an important role of the locus
coeruleus and cerebellum to the essential tremor has been
strongly suggested [16, 17].
Harmaline, a derivative of β-carboline is a well-known
tremorgenic compound which has been suggested to model
essential tremor in animals [18]. Harmaline induces the
action and postural tremor in several animal species which
is manifested by the tremor of fore and hind limbs, head
tremor or generalized tremor of the whole body [18–21].
Oscillation frequency in this tremor decreases with increas-
ing weight of an animal and is equal to 11–14 Hz in mice,
10–12 Hz in rats, and 8–10 Hz in monkeys [18]. Although
a synchronous activation of the olivo-cerebellar pathway
and release of glutamate in the cerebellum which acts at
NMDA and AMPA receptors has been suggested to be a
primary cause of the harmaline-induced tremor [18, 22, 23],
the mechanisms underlying this symptom seem to be
complex and may involve also noradrenergic, serotonergic,
dopaminergic, and GABA-ergic systems [23–26], as well as
some distant brain structures, e.g., reticular formation,
caudate–putamen, frontal cortex, and others [27–29]. The
latter assumption is based on the fact that a systemic
harmaline administration in tremorgenic doses induces
metabolic and neuronal activation in the above structures
[27–29]. Moreover, since harmaline has been found to
modulate postural tremor induced by a lesion of the
substantia nigra in monkeys [30], some interrelationship
between neuronal alterations triggered by harmaline and
those underlying tremor induced by degeneration of
dopaminergic neurons may be suggested.
The aim of the present study was to examine an
influence of lesions of the cerebellar catecholaminergic
innervations on the harmaline-induced tremor and bio-
chemical alterations in this structure, as well as in the
substantia nigra, caudate–putamen and frontal cortex in
rats. To this aim, 6-hydroxydopamine (6-OHDA) was
administered directly into the cerebellum alone or in
combination with desipramine, in order to simultaneously
produce a lesion of dopaminergic and noradrenergic
terminals or only dopaminergic innervation, respectively.
Materials and Methods
The experiments were carried out in compliance with the
Animal Protection Bill of August 21, 1997; (published in
Journal of Laws no. 111/1997 item 724), and according to
the NIH Guide for the Care and Use of Laboratory
Animals. They received also an approval of Local Ethical
Committee. All efforts were made to minimize the number
and suffering of animals used.
Male Wistar rats weighing 220–250 or 350–380 g
(assigned for operations) prior to experiments were kept
on a light/dark cycle (12/12 h; the light on from 7 am to
7 pm) with free access to food and water.
Operations
Under the pentobarbital anesthesia (Vetbutal, Biowet,
Poland; 25 mg/kg, i.p.) the animals were fixed into the
stereotaxic instrument (Stoelting, USA) and injected with 6-
OHDA into the cerebellum. Tips of injection cannulae were
placed at the border between lobules 9 and 10 of the
cerebellar vermis (AP: −13.2 mm, L: ±1.3, V: 6.6 mm, in
reference to Bregma, according to Paxinos and Watson’s
atlas [31]). 6-OHDA HBr (Sigma, Aldrich) was dissolved
in a 0.05% ascorbic acid and injected bilaterally into the
cerebellum in a dose of 8 μg/0.5 μl/side using a 1 μl
Hamilton syringe with a speed 0.1 μl/30 s. The injection
cannulae were left in place for 60 s in order to enable
absorption of the solution. Control (sham-operated) rats
received 0.5 μl of ascorbic acid solution bilaterally into the
aforementioned region of the cerebellum. In order to spare
noradrenergic terminals, a group of rats was injected with
desipramine (Sigma-Aldrich, Germany) in a dose of 15 mg/
2 ml/kg ip 30 min before intrastructural injections. In order
to avoid infections, the rats received an antibiotic (Linco-
spectin, Pharmacia, Belgium, 0.1 ml/kg) 24 h before the
operation, on the day of operation and 24 h afterwards.
Behavioral Observations
Rats were weighed on the day of operation, as well as 1, 3,
7, and 9 days afterwards. The open field test was carried out
on the eighth day after the operation. The field was a square
(60×70 cm) surrounded by a wall of 30 cm high having 10
holes (two and three in each shorter and longer side,
respectively) and was illuminated by white light emitted by
a bulb located above its center. Rats were placed individ-
ually at the center of the field and their behavior was
evaluated during a 10-min session. Time spent for
locomotor activity or grooming, and the number of rearings
and peepings into holes were measured.
Harmaline (Sigma, Germany) was dissolved in sterile
water and injected in a dose of 7.5 mg/kg ip on the ninth
268 Cerebellum (2011) 10:267–280day after the operation. Rats were placed individually in a
Plexiglas cage (40×40×25 cm) and video recordings of
their behavior were taken during 90 min after harmaline
injections. This behavior was analyzed afterwards and
quantified according to the procedures described earlier
[21]. Briefly, the tremor of forelimbs was measured by a
number of episodes, while hind leg abduction and balance
disturbances were scored semi-quantitatively according to
the arbitrarily accepted three-point scales. After finishing
the behavioral experiments, the rats were killed by
decapitation and the localization of their cannula tips were
examined on histological slices stained with the Nissl
method (Fig. 1).
Biochemical HPLC Analyses of Monoamines and Their
Metabolites (According to Modified Methods [32, 33])
Naïve or operated rats (on the ninth day after the operation)
were treated with harmaline in doses of 7.5 or 15 mg/kg ip
and killed by decapitation 30 or 120 min after injections.
Their brains were rapidly removed and dissected on a
chilled plate using curved micro-forceps. First, the sub-
stantia nigra was separated from the mesencephalon at the
level of oculomotor nerve root and excised. Then, the
frontal cortex was detached by a vertical cut carried out at
the level ca. AP=+4.5 mm with reference to the bregma
(according to Paxinos and Watson [31]). Afterwards, the
whole caudate–putamen was exposed and taken out.
Finally, the cerebellar lobules 1–3, 4–7, and 8–10 (contain-
ing both corresponding vermis and hemispheres) were
excised by cuts carried out along respective fissures. The
tissues were immediately frozen and stored at −80°C until
further procedures were applied.
Levels of dopamine and its metabolites—3,4-dihydrox-
yphenylacetic acid (DOPAC), 3-methoxytyramine (3-MT),
homovanillic acid (HVA), serotonin (5-HT), its metabolite—
5-hydroxyindoleacetic acid (5-HIAA), noradrenaline, and in
some cases 3-methoxy-4-hydroxy-phenylethyleneglycol
(MOPEG) were assessed using an HPLC method with
electrochemical detection.
Tissue samples were homogenized in 0.1 M perchloric
acid containing 0.05 mM ascorbic acid. Tissue homoge-
nates were then centrifuged (10,000×g,1 5m i n ,4 ° C ) ,
filtered through 0.2 μm cellulose membrane, centrifuged
again (4,000×g, 3 min, 4°C) and injected into the system
that consisted of thermally controlled ASI-100 autosam-
pler (4°C), P680 isocratic pump with degasser (Dionex,
Germany), column [Hypersil, 150×3.0 mm, 3 μm( f o rt h e
caudate–putamen and frontal cortex) or 4.6 mm, 3 μm( f o r
the cerebellar lobules and substantia nigra), Thermo
Scientific, UK], TCC-100 thermally controlled column
compartment [32°C (for the caudate–putamen and frontal
cortex) or 22°C (for the cerebellar lobules and substantia
nigra), Dionex, Germany], and electrochemical detector
analytic cell 5010 Coulochem III (ESA, Inc. USA). The
mobile phase for the caudate–putamen and frontal cortex
was composed of 50 mM NaH2PO4×2H2O, 40 mM citric
acid, 0.25 mM 1-octanesulfonic acid sodium salt,
0.25 mM EDTA, 1.3% acetonitrile, and 2.4% methanol.
The mobile phase for the cerebellar lobules and substantia
nigra consisted of 75 mM NaH2PO4×2H2O, 1.7 mM 1-
octanosulfonic acid, 5 μM EDTA, 100 μl of triethylamine/
1 l, 9.5% acetonitrile, and phosphoric acid (pH=3). The
flow rate was 0.7 ml/min. The applied potential was E1=–
175 or −50 mV and E2=+350 mV.
The data were quantified using the area under the peaks
and external standards, using Chromeleon software (Dionex,
Germany). The turnover of amines was calculated as
metabolite to neurotransmitter ratio.
Statistics
The data related to tremor and weight was analyzed by
ANOVA for repeated measures and least significant
-12.8 mm 
                     
-13.2 mm 
                        
-13.3 mm 
                   
IX 
X 
IX 
X 
IX 
X 
Fig. 1 Histologically confirmed localization of cannula tips (filled
circles) shown in frontal sections of the rat cerebellum in reference to
bregma according to Paxinos and Watson [31]. Roman numbers
indicate respective lobules
Cerebellum (2011) 10:267–280 269difference (LSD) post hoc test. The biochemical data were
analyzed either by two-way ANOVA and LSD post hoc test
(naïve rats) or one-way ANOVA and LSD post hoc test
(operated rats). All statistical calculations were done using
STATISTICA 7.0 Software (Statsoft, Inc. USA).
Results
Behavioral Observations
Spontaneous Behavior
During the first 24 h after the operation all animals (sham-
operated and lesioned) lost their weight to a similar degree
(>20 g). During the following days, however, the weight of
rats which received 6-OHDA (8 μg/0.5 μl) with or without
desipramine (15 mg/kg ip) further decreased while that of
sham-operated animals returned to the almost normal level
on the ninth day after the operation (Fig. 2).
Analysis of rats’ behavior in the open field test carried out
ontheeighthdayafteroperationdidnotrevealanydifferences
between sham-operated and lesioned rats which received 6-
OHDA with or without desipramine with respect to the time
spentforlocomotoractivity,grooming,thenumberofrearings
and peepings into holes (data not shown).
Harmaline-Induced Behavior
Preliminary observation of behavior of naïve rats injected
with harmaline indicated that similar to our previous study
[21] the lower dose of this compound (7.5 mg/kg ip)
induced intensive tremor of the forelimbs and the whole
body, as well as balance disturbances, hind leg abduction,
and an increase in locomotor activity which lasted longer
than 90 min. The tremor induced by the higher dose
(15 mg/kg ip) was ca. 70% more intensive than that of the
lower one and balance disturbances were so strong that
animals fell down during any attempt to move which
precluded observation and quantification of forelimb
tremor. Therefore, for further examination of an influence
of cerebellar lesions on the latter symptom, the lower dose
(7.5 mg/kg ip) of harmaline was chosen.
Rats lesioned with 6-OHDA (without desipramine)
exhibited a marked and statistically significant increase in
the harmaline-induced tremor of forelimbs. That effect was
the strongest between 30 and 60 min after administration of
this drug (Fig. 3). In contrast, the lesion induced by 6-
OHDA injected together with desipramine (15 mg/kg ip)
did not influence forelimb tremor induced by harmaline
(Fig. 3). Moreover, both types of 6-OHDA-induced lesions
did not alter balance disturbances and hind leg abduction
evoked by harmaline (data not shown).
An Influence of Harmaline on Dopamine, Noradrenaline,
Serotonin, and Their Metabolites in Brain Structures
Dopamine and Metabolites
Caudate–Putamen, Substantia Nigra, Frontal Cortex Har-
maline administered in naïve rats in a dose of 7.5 mg/kg ip
did not significantly influence dopamine levels in the
caudate–putamen and substantia nigra, but decreased it in
the frontal cortex 30 min after the administration (Fig. 4).
Harmaline in a dose of 15 mg/kg increased the level of
dopamine in the caudate–putamen and reduced it in the
substantia nigra 30 and 120 after administration, respec-
tively. In the frontal cortex, the level of this neurotransmit-
ter was not lowered significantly by the latter dose of
Fig. 2 Loss of body weight of rats with lesions of catecholaminergic
cerebellar innervations. The results are shown as the mean±SEM.
Abscissa days after the operation. The number of animals n=4–7 per
group. 6-OHDA 6-hydroxydopamine, DES desipramine. ANOVA for
repeated measures and LSD post hoc test, *p<0.05 vs. sham
Fig. 3 An influence of lesions of catecholaminergic cerebellar
innervations on the harmaline-induced (7.5 mg/kg ip) tremor of
forelimbs of rats. Abscissa time after harmaline administration. The
results are shown as the mean±SEM. The number of animals n=4–7
per group. 6-OHDA 6-hydroxydopamine, DES desipramine. ANOVA
for repeated measures and LSD post hoc test, *p<0.05 vs. SHAM,
&p
<0.05 vs. 6-OHDA
270 Cerebellum (2011) 10:267–280harmaline, but a trend (0.05<p<0.1) in this direction was
observed 120 min after the injection (Fig. 4).
Harmaline administered in doses of 7.5 and 15 mg/kg
profoundly decreased the levels of DOPAC, HVA, as
well as DOPAC/dopamine ratios in the caudate–putamen,
substantia nigra, and frontal cortex (Fig. 4,T a b l e1).
HVA/dopamine ratios were additionally diminished in the
caudate–putamen, substantia nigra (30 and 120 min) after
both aforementioned doses and in the frontal cortex after
the lower dose of this drug 120 min after injection
(Table 1). In contrast, the higher dose of harmaline
significantly elevated the HVA/dopamine ratio in the
frontal cortex, but only 30 min after administration
(Table 1).
Harmaline administered in both doses increased 3-MT
levels and 3-MT/dopamine ratios in the caudate–putamen,
substantia nigra, and frontal cortex (Fig. 4, Table 1).
Cerebellum Harmaline administered in a lower dose
(7.5 mg/kg) did not influence the level of dopamine in the
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Fig. 4 The effect of harmaline (7.5 and 15 mg/kg) on the levels of
dopamine (DA) and its metabolites: DOPAC, HVA, and 3-MT in
different brain structures. Rats were killed 30 or 120 min after
harmaline administration. CP caudate–putamen, SN substantia nigra,
FC frontal cortex, lob 1–3 lobules 1–3, lob 4–7 lobules 4–7, lob 8–10
lobules 8–10 of the cerebellum, n.a. not analyzed, n.d. not detected.
The number of animals n=6–8 per group. The results are shown in
nanogram per gram tissue (mean±SEM). Two-way ANOVA and LSD
post hoc test. *p<0.05 vs. solvent,
&p<0.05 vs. lower dose of
harmaline,
#0.05<p<0.1 vs. solvent
Cerebellum (2011) 10:267–280 271cerebellum, but lowered DOPAC and DOPAC/dopamine
r a t i oi nl o b u l e s8 –10 (Fig. 4,T a b l e1) .T h eh i g h e rd o s eo f
harmaline (15 mg/kg) decreased the level of DOPAC and
DOPAC/dopamine ratio in lobules 8–10 at 30 min, but
produced an opposite effect at 120 min after administra-
tion (Fig. 4,T a b l e1). Moreover, the level of dopamine
(30 min), DOPAC (30 and 120 min) and DOPAC/
dopamine ratio (120 min) were elevated in lobules 1–3
after the latter dose of harmaline (Fig. 4,T a b l e1). HVA
levels were diminished in lobules 1–3 after both the
aforementioned doses of harmaline, but only 120 min after
administration (Fig. 4). 3-MTwas not detectable in lobules
1–3o ri n8 –10 (Fig. 4).
Serotonin, Noradrenaline, and Their Metabolites
Caudate–Putamen, Substantia Nigra, Frontal Cortex Har-
maline administered in doses of 7.5 and 15 mg/kg did not
Table 1 An influence of harmaline (7.5 and 15 mg/kg) on metabolites/monoamines ratios in different brains structures in naïve rats 30 or 120 min
after injections
30 min 120 min
Solvent Harmaline 7.5 Harmaline 15 Solvent Harmaline 7.5 Harmaline 15
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
DOPAC/DA
CP 0.1329 0.0055 0.0457* 0.0128 0.0301* 0.0033 0.0998 0.0017 0.0208* 0.0055 0.0135* 0.0015
SN 0.3271 0.0260 0.2214 0.0783 0.0457* 0.0143 0.3418 0.0800 0.1450* 0.0434 0.0436* 0.0206
FC 0.3756 0.0200 0.2453* 0.0234 0.2585
# 0.0246 0.3627 0.0532 0.1339* 0.0172 0.1767* 0.0070
lob 1–3 0.3689 0.0615 0.1725 0.0180 0.3808 0.1383 0.1533 0.0240 0.5271 0.0823 1.7648* 0.7858
lob 8–10 3.0460 0.7738 0.6156* 0.1557 1.2188* 0.2789 1.2795 0.2575 0.1083 0.0188 2.1510 0.6204
HVA/DA
CP 0.1329 0.0059 0.0755* 0.0116 0.0703* 0.0058 0.1278 0.0048 0.0180* 0.0054 0.0100* 0.0016
SN 0.2656 0.0256 0.1414* 0.0224 0.1045* 0.0161 0.2511 0.0477 0.1561* 0.0364 0.1377* 0.0152
FC 0.5886 0.0324 0.6070 0.0499 0.9199* 0.1081 0.6905 0.0856 0.3051* 0.0326 0.5087 0.0368
lob 1–3 8.6609 2.2380 3.8118 0.5272 3.3600 1.3956 5.6623 0.8068 4.1700 1.2064 4.0330 1.7805
lob 8–10 – – –– –– – – –– ––
3-MT/DA
CP 0.0363 0.0022 0.0614* 0.0063 0.0656* 0.0056 0.0288 0.0018 0.0747* 0.0071 0.0765* 0.0037
SN 0.2964 0.1157 0.1670 0.0395 0.4373 0.0727 0.0813 0.0163 0.3557* 0.0710 0.7096* 0.1318
FC 0.0850 0.0181 0.3268
# 0.0438 0.3819* 0.0714 0.1296 0.0193 0.3237* 0.0654 0.6405* 0.0856
lob 1–3 – – –– –– – – –– ––
lob 8–10 – – –– –– – – –– ––
5-HIAA/5-HT
CP 1.1462 0.0495 0.8130* 0.0694 0.9378 0.0469 1.2418 0.0435 0.5906* 0.0732 0.5635* 0.0320
SN 0.4548 0.1007 0.4959 0.0581 0.5283 0.0828 0.8242 0.1078 0.3948* 0.0350 0.3762* 0.0520
FC 1.6240 0.1261 0.5977* 0.0261 0.7057* 0.0341 1.5969 0.2575 0.5484* 0.0717 0.4903* 0.0326
lob 1–3 3.4631 0.4753 1.2206* 0.0375 1.6151* 0.1775 2.4187 0.1319 1.1709 0.1393 3.0202* 1.2923
lob 8–10 2.7490 0.3183 0.5090* 0.0718 0.5731* 0.0724 2.8208 0.4875 0.4327* 0.0335 0.5066* 0.0299
MOPEG/NA
CP – – –– –– – – –– ––
SN – – –– –– – – –– ––
FC 0.0854 0.0232 0.0237* 0.0063 0.0205* 0.0060 0.0078 0.0010 0.0058 0.0010 0.0046 0.0005
lob 1–3 – – –– –– – – –– ––
lob 8–10 – – –– –– – – –– ––
Two-way ANOVA and LSD post hoc test
CP caudate–putamen, FC frontal cortex, SN substantia nigra, lob 1–3 lobules 1–3, lob 8–10 lobules 8–10 of the cerebellum
*p<0.05 vs. solvent,
# 0.05<p<0.1 vs. solvent
272 Cerebellum (2011) 10:267–280influence the serotonin level in the caudate–putamen and
substantia nigra, but increased it in the frontal cortex. The
5-HIAA level was strongly lowered in the frontal cortex
(30 min and 120 after harmaline), and in the caudate–
putamen and substantia nigra (120 min after harmaline;
Fig. 5). 5-HIAA/serotonin ratios were decreased in all the
above structures (Table 1).
The noradrenaline level was not altered by harmaline in
the caudate–putamen and substantia nigra. However, this
compound in the higher dose (15 mg/kg) increased the level
of this neurotransmitter in the frontal cortex (Fig. 5).
Moreover, both doses reduced the MOPEG/noradrenaline
ratio in the latter structure (Table 1).
Cerebellum The level of serotonin was increased in the
lobules 1–3 and 8–10 after both doses of harmaline (Fig. 5).
In the lobules 8–10, the level of 5-HIAA strongly declined
30 min after the lower dose of harmaline; and in lobules 1–
3 and 8–10, 120 min after both doses of this compound
(Fig. 5). The 5-HIAA/serotonin ratio also decreased in the
aforementioned cerebellar regions, with one exception—in
lobules 1–3, it was elevated after the higher dose of
harmaline 120 min after administration (Table 1).
The noradrenaline level was significantly enhanced after
the lower dose of harmaline (7.5 mg/kg) in lobules 8–10
(30 min and 120 min after administration) and in lobules 1–
3 (120 min after administration; Fig. 5). The higher dose of
this compound increased significantly the level of this
neurotransmitter only in lobules 8–10 at 30 min, but not at
120 min after administration. Moreover, this enhancement
was significantly lower than that produced by the lower
dose (Fig. 5). The MOPEG levels were not detected in the
cerebellum (Table 1).
An Influence of Lesions of Catecholaminergic Innervations
of the Cerebellum on Dopamine, Noradrenaline, Serotonin,
and Their Metabolites in Brain Structures
Intracerebellar Injections of 6-OHDA
Cerebellum 6-OHDA injected in a dose of 8 μg/0.5 μl
bilaterally into the lobules 9–10 dramatically decreased the
noradrenaline level (by 84%) in lobules 8–10 and to a lesser
extent in lobules 4–7 (by 51%) but did not significantly
influence the level of this neurotransmitter in lobules 1–3
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Fig. 5 The effect of harmaline (7.5 and 15 mg/kg) on the levels of serotonin (5-HT), 5-HIAA and noradrenaline (NA) in different brain
structures. For further explanations, see Fig. 4
Cerebellum (2011) 10:267–280 273(Fig. 7). Furthermore, the above injection enhanced the
dopamine level and diminished the HVA/dopamine ratio
in lobules 8–10, and tended (0.05<p<0.1)tolowerthe3-
MT/dopamine ratio in lobules 4–7( F i g .6,T a b l e2). The 5-
HIAA level in lobules 4–7 was additionally decreased
(Fig. 7).
Caudate–Putamen, Substantia Nigra, Frontal Cortex The
levels of both serotonin and 5-HIAA in the substantia nigra
and the noradrenaline level in the caudate–putamen were
increased after intracerebellar 6-OHDA injections (Fig. 7).
No other alterations in neurotransmitter or their metab-
olites levels were observed in any structures examined
(Figs. 6 and 7).
Intracerebellar Injections of 6-OHDA Together
with Desipramine
Cerebellum 6-OHDA injected in a dose of 8 μg/0.5 μl
bilaterally into the lobules 9–10 30 min after desipramine
(15 mg/kg ip) slightly decreased the noradrenaline level in
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Fig. 6 An influence of lesions of cerebellar catecholaminergic
innervations on the levels of dopamine (DA) and its metabolites in
different brain structures in untreated (left panel) or harmaline-treated
(7.5 mg/kg, right panel) rats. The animals were sacrificed on the ninth
day after the operation, 120 min after harmaline injection. CP
caudate–putamen, FC frontal cortex, SN substantia nigra, lob 1–3
lobules 1–3, lob 4–7 lobules 4–7, lob 8–10 lobules 8–10 of the
cerebellum, n.d. not detected. The results are shown in nanogram per
gram tissue (mean±SEM). The number of animals n=8–12. One-way
ANOVA and LSD post hoc test. *p<0.05 vs. sham,
&p<0.05 vs. 6-
OHDA,
#0.05<p<0.1 vs. sham
274 Cerebellum (2011) 10:267–280lobules 4–7 (by 18%) and 8–10 (by 19%) but raised it in
lobules 1–3 (by 100%; Fig. 7). Moreover, the above
injections attenuated the DOPAC level and the DOPAC/
dopamine, 3-MT/dopamine and HVA/dopamine ratios in
lobules 4–7 (Fig. 6, Table 2). In contrast, the levels of
dopamine in lobules 1–3, DOPAC, HVA and HVA/
dopamine ratio in lobules 8–10 and/or 1–3 were increased
significantly (Fig. 6,T a b l e2). The above injection
decreased additionally the 5-HIAA level and tended to
lower that of 5-HT in the lobules 4–7 of the cerebellum
(Fig. 7) but elevated the 5-HIAA/5-HT ratio in the lobules
8–10 (Table 2).
Caudate–Putamen, Substantia Nigra, Frontal Cortex 6-
OHDA in a dose of 8 μg/0.5 μl injected bilaterally into the
lobules 9–10, 30 min after desipramine (15 mg/kg ip)
reduced the level of noradrenaline in the substantia nigra
(Fig. 7). No other alterations in neurotransmitters and their
metabolites were observed either in the above structure, in
the caudate–putamen, or in the frontal cortex.
Table 2 An influence of lesions of cerebellar catecholaminergic innervations on metabolites/monoamines ratios in different brain structures in
rats untreated (left panel) or treated with harmaline (7.5 mg/kg ip; right panel)
Control Harmaline 7.5 mg/kg
Sham 6-OHDA 6-OHDA+DES Sham 6-OHDA 6-OHDA+DES
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
DOPAC/DA
CP 100.00 4.04 98.93 3.65 98.34 3.75 100.00 13.44 103.51 13.27 107.12 15.46
SN 100.00 5.26 88.41 5.48 90.32 5.67 100.00 11.04 84.08 13.47 137.89* 23.89
FC 100.00 4.62 101.35 5.25 105.70 3.48 100.00 5.08 96.93 9.41 103.29 8.06
lob 1–3 100.00 12.38 124.49 10.78 110.88 12.27 100.00 13.85 72.79 5.08 81.64 10.90
lob 4–7 100.00 32.84 70.23 32.71 18.19* 2.70 100.00 4.63 127.30 11.20 120.22 14.55
lob 8–10 100.00 10.89 79.44 16.21 105.22 19.89 100.00 13.48 105.62 9.41 192.94*
,& 27,90
HVA/DA
CP 100.00 6.21 96.08 6.29 106.24 2.43 100.00 17.97 111.40 21.25 120.70 23.37
SN 100.00 7.13 87.22 5.56 111.06
& 7.89 100.00 9.21 106.39 14.52 63.10*
,& 9.28
FC 100.00 6.85 85.07 6.97 94.47 3.51 100.00 7.42 112.73 8.24 87.08
& 5,25
lob 1–3 –– –– – – –– –– – –
lob 4–7 100.00 9.03 125.57 27.43 61.94*
,& 7.47 100.00 10.15 102.79 10.46 112.80 13.15
lob 8–10 100.00 15.67 45.06* 5.68 115.43
# 24.50 –– –– – –
3-MT/DA
CP 100.00 5.12 96.14 4.50 86.21 3.99 100.00 5.62 101.93 7.04 105.66 9.16
SN 100.00 19.97 97.35 23.56 80.95 22.87 100.00 4.83 113.38 11.95 100.74 3.95
FC –– –– – – –– –– – –
lob 1–3 –– –– – – –– –– – –
lob 4–7 100.00 17.19 56.29
# 20.68 448.74* 11.77 100.00 12.43 128.15 27.45 122.20 43.98
lob 8–10 –– –– – – –– –– – –
5-HIAA/5-HT
CP 100.00 2.22 98.62 2.29 106.32 4.90 100.00 4.91 113.46 6.59 108.21 10.15
SN 100.00 3.30 112.06 5.67 110.50 6.79 100.00 5.70 104.09 3.53 103.41 5.56
FC 100.00 4.47 97.00 2.88 100.16 4.10 100.00 6.85 108.39 6.71 120.61 12.76
lob 1–3 100.00 10.24 138.27 20.62 126.90 23.09 100.00 8.82 100.14 6.50 116.19 13.37
lob 4–7 100.00 9.71 81.75 9.60 86.25 8.20 100.00 4.62 98.99 6.50 76.37*
,& 9.35
lob 8–10 100.00 6.55 89.51 5.72 128.56*
,& 10.40 100.00 12.91 124.96 15.52 111.76 8.57
One-way ANOVA and LSD post hoc test
DES desipramine, CP caudate–putamen, FC frontal cortex, SN substantia nigra, lob 1–3 lobules 1–3, lob 4–7 lobules 4–7, lob 8–10 lobules 8–10
of the cerebellum
*p<0.05 vs. respective sham,
#0.05<p<0.1 vs. respective sham,
&p<0.05 vs. 6-OHDA
Cerebellum (2011) 10:267–280 275An Influence of Lesions of Catecholaminergic Innervations
of the Cerebellum on the Harmaline-Induced Alterations
of Dopamine, Noradrenaline, Serotonin,
and Their Metabolites in Brain Structures
Intracerebellar Injections of 6-OHDA
All biochemical measurements were carried out in rats treated
with 7.5 mg/kg of harmaline 120 min after its ip injections.
Cerebellum 6-OHDA injected in a dose of 8 μg/0.5 μl
bilaterally into the lobules 9–10 dramatically decreased the
noradrenaline level in lobules 8–10 (by 84%) and to a lesser
extent in lobules 4–7 (by 28%) but did not influence the
level of this neurotransmitter in lobules 1–3 after harmaline
(Fig. 7). The above lesion did not influence the dopamine
level in the cerebellum, but increased the DOPAC level in
lobules 4–7 (Fig. 6).
Caudate–Putamen, Substantia Nigra, Frontal Cortex 6-
OHDAwas injected in a dose of 8 μg/0.5 μl bilaterally into
the lobules 9–10 increased the serotonin and 5-HIAA levels
in the caudate–putamen and frontal cortex in the harmaline-
treated rats (Fig. 7). In the substantia nigra, only the
DOPAC/dopamine ratio was reduced in the harmaline-
treated rats (Table 2).
Intracerebellar Injections of 6-OHDA Together
with Desipramine
All biochemical measurements were carried out in rats treated
with 7.5 mg/kg of harmaline 120 min after its ip injections.
Cerebellum 6-OHDA in a dose of 8 μg/0.5 μli n j e c t e d
bilaterally into the lobules 9–10, 30 min after desipramine (15
mg/kg ip), decreased the noradrenaline level by ca. 36% in
lobules 8–10 but did not change it in any other cerebellar
regions inratstreated with harmaline (Fig. 7). In contrast, this
lesion increased the DOPAC level and DOPAC/dopamine
ratio in lobules 8–10 (Table 2, Fig. 6). The serotonin level
was increased and 5-HIAA/serotonin ratio decreased in
lobules 4–7( F i g .7). In contrast, the level of serotonin was
not changed in lobules 1–3a n d8 –10, but the 5-HIAA/
serotonin ratio was increased in the latter region (Table 1).
Caudate–Putamen, Substantia Nigra, Frontal Cortex 6-
OHDA injected in a dose of 8 μg/0.5 μl bilaterally into the
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276 Cerebellum (2011) 10:267–280lobules 9–10 30 min after desipramine (15 mg/kg ip)
increased the DOPAC level in the substantia nigra in rats
treated with harmaline (Fig. 6). In the latter structure, the
HVA level was not significantly changed, but the HVA/
dopamine ratio was diminished (Table 2, Fig. 6).
Discussion
The most important result of the present study is the finding
that 6-OHDA injected bilaterally into the cerebellum
enhanced the harmaline-induced tremor of forelimbs. The
cerebellum receives two catecholaminergic projections: a
weak dopaminergic pathway arising from the region
comprising the ventral tegmental area and/or substantia
nigra, and an intensive noradrenergic projection from the
pontine locus coeruleus [10–14]. It was presumed that 6-
OHDA injected alone would destroy terminals of both
catecholaminergic inputs to the cerebellum. Examination of
the lesion extent was carried out biochemically. This
analysis revealed that 6-OHDA dramatically reduced the
noradrenaline level in the region of cannulae placement
(lobules 8–10) and to a lesser extent in the neighboring
cerebellar region (lobules 4–7) in animals. Only the most
rostral part of the cerebellum (lobules 1–3) was spared. In
contrast, however, a lesion of dopaminergic system seemed
to be very small and compensated for. Only dopamine
turnover measured by the ratios for its extracellular
metabolite 3-MT/dopamine (cf. [34]) and HVA/dopamine
was reduced in some regions of the cerebellum, but the
level of this neurotransmitter was not decreased but even
increased.
In contrast to 6-OHDA administered alone, this toxin
injected together with desipramine, in order to protect
noradrenergic terminals, did not influence the harmaline-
induced forelimb tremor. Although such treatment did not
decrease the level of dopamine in the cerebellum in rats, it
lowered dramatically the DOPAC level and dopamine
turnover (measured by all metabolites/dopamine ratios) in
the lobules 4–7. In contrast, the levels of dopamine, its
metabolites (DOPAC, HVA) and turnover (measured by the
ratio for its final metabolite—HVA/dopamine) were in-
creased in neighboring regions of the cerebellum. The
above biochemical data seem to suggest that some
dopaminergic terminals in the region of lobules 4–7 were
destroyed by the toxin that triggered a compensatory
response in other parts of the cerebellum. The affected
region was not located close to the cannulae tips (lobules 8–
10), which seems to suggest that while noradrenergic
terminals were protected by desipramine, the 6-OHDA
solution further diffused across the cerebellum after
injection. The dopaminergic innervation in the cerebellum
is rather low [10–13] and, therefore, only a small amount of
the toxin could be taken up by these terminals at the site of
injection. However, such treatment appeared to be not fully
selective because small decreases in noradrenaline levels in
lobules 4–7 and 8–10, as well as serotonin and 5-HIAA in
lobules 4–7 were noted. These alterations seemed to be also
compensated for which was visible as an increase in the
noradrenaline level and serotonin turnover in neighboring
cerebellar regions.
Summing up, the above comparison of biochemical
effects of treatments with 6-OHDA alone and together with
desipramine strongly indicates that the lesion of noradren-
ergic (but not dopaminergic) cerebellar terminals was
responsible for enhancement of the harmaline-induced
forelimb tremor and implies for the first time an inhibitory
influence of the cerebellar noradrenergic innervation on this
symptom. These results are in a good agreement with the
previous study of Yamazaki et al. [25] who found that a
lesion of the locus coeruleus enhanced the harmaline-
induced tremor, whereas stimulation of this structure or
injections of L-threo-DOPS (a noradrenaline precursor
[35]) which increased the level of noradrenaline in several
brain structures, including the cerebellum, decreased this
symptom in rats.
Harmaline is a highly selective, reversible inhibitor of
MAO-A (an enzyme preferentially deaminating dopamine,
noradrenaline and serotonin [36]), which blocks this
enzyme’s isoform in nanomolar concentrations [37]. In
accordance with this mechanism, harmaline administered in
the present study reduced tissue levels of DOPAC, HVA, 5-
HIAA, and increased the level of serotonin and noradren-
aline in most of the structures examined, including
cerebellum. Although in vivo microdialysis studies after
harmaline administration are lacking, it may be expected
that this compound increases extracellular levels of mono-
amines in the above structures. This suggestion is based on
previous studies which showed that other MAO-A inhib-
itors (including another β-carboline derivative—harman
[38]), increased extracellular levels of dopamine [37, 39–
41], noradrenaline [37, 39], and serotonin [39, 42]i n
different brain structures. In an agreement with the above
results, the present study showed elevated levels of the
extracellular dopamine metabolite—3-MT (cf. [34]) in the
caudate–putamen, substantia nigra, and frontal cortex after
harmaline administration. Therefore, in the light of the
present findings showing that a lesion of cerebellar
noradrenergic innervation increases the harmaline-induced
tremor, the question arises what is the contribution of the
enhanced noradrenergic transmission evoked by this com-
pound to this symptom. However, we found additionally
that the above lesion induced by 6-OHDA administered
alone strongly lowered the noradrenaline level in lobules 8–
10 and to a lesser extent in lobules 4–7 in the harmaline-
Cerebellum (2011) 10:267–280 277treated animals. When 6-OHDA was administered together
with desipramine, some decline in noradrenaline level in
the harmaline-treated animals was also observed in lobules
8–10; however, it seemed to be too low to influence the
tremor evoked by this compound. These results seem to
suggest that the increased noradrenergic transmission
induced by harmaline in the cerebellum may counteract
the tremor induced by this compound. This view is
supported also by the present results demonstrating that
increases in the noradrenaline level in the cerebellum
induced by this compound in naïve rats showed a U-
shaped dose dependency. It appeared that the elevation of
the cerebellar level of this neurotransmitter induced by the
higher dose of this drug (15 mg/kg), which induced
extremely strong tremor, was much weaker and shorter
than that evoked by the lower dose (7.5 mg/kg) after which
this symptom was only moderate.
Increased synchronous oscillatory activity of the neurons
of the inferior olive and olivo-cerebellar climbing fibers,
which induces release of glutamate in the cerebellum and
rhythmic firing pattern of complex spikes of the Purkinje
cells, has been suggested to be the primary cause of the
harmaline-inducedtremor[18, 22, 23]. Oscillatory activity of
the inferior olive neurons has been found to be blocked by
noradrenaline [43]; however, cerebellar mechanisms by
which this neurotransmitter inhibits tremor cannot be easily
specified. Electrophysiological studies indicated that nor-
adrenaline suppressed spontaneous firing of Purkinje cells
and induced their hyperpolarization (for ref. see [44]).
However, it also modulated synaptic actions increasing both
the excitatory (induced by activation of climbing fibers) and
inhibitory (evoked by stimulation of spontaneous firing of
GABA-ergic interneurons—basket cells) influences on Pur-
kinje cells [44–46]. Therefore, it seems that the role of
cerebellar noradrenaline is mainly modulatory and it serves
to keep homeostasis in this structure. The lack of this
neurotransmitter increased susceptibility of this structure to
pathological oscillations.
The lesion of noradrenergic terminals in the cerebellum
induced compensatory alterations also in distant structures;
namely, it increased the noradrenaline level in the caudate–
putamen and the serotonin and 5-HIAA levels in the
substantia nigra. Moreover, this lesion enhanced serotonin
and 5-HIAA levels in the caudate–putamen and frontal
cortex in rats treated with harmaline. The latter result seems
to indicate a contribution of the increased serotonergic
transmission to the harmaline-induced tremor. Such rela-
tionship has already been strongly suggested by others. It
has been found that the inhibition of serotonin synthesis by
systemic administration of p-chlorophenylalanine (PCPA—
a tryptophan hydroxylase inhibitor [26]), or a lesion of
serotonergic brain system induced by intraventricular 5,6-
or 5,7-dihydroxytryptamine injections [24], decreased this
symptom, whereas serotonin reuptake inhibitors (selective
—citalopram, or non-selective—imipramine) enhanced it
[47, 48]. A number of studies have suggested that
activation of serotonergic system at the level of the inferior
olive and the cerebellum was responsible for the aforemen-
tioned enhancement of the harmaline-induced tremor.
Similar to the present study, harmaline reportedly increased
the serotonin level in the cerebellum and inferior olive [26,
47, 48], while PCPA or serotonergic toxins decreased it
[26], and reversed the harmaline-induced activation of
climbing fibers [24]. Moreover, stimulation of 5-HT2A
receptors in the inferior olive increased an average firing
rate, rhythmicity, and synchronicity of complex spikes in
Purkinje cells [49]. Our present results extend former
studies and seem to suggest for the first time that the
increased serotonergic transmission in the caudate–putamen
and frontal cortex may also contribute to the harmaline-
induced tremor.
Serotonergic transmission has also been suggested to
contribute to the tremor induced by acetylcholinesterase
inhibitors: organophosphates [50], physostigmine [51–53],
and tacrine [54–56], which has been suggested to result
from activation of the striatal cholinergic transmission [54].
A number of findings showed consistently that these
compounds enhanced also the level of serotonin, and its
turnover or release in several brain structures including the
inferior olive, cerebellum, striatum, substantia nigra, cere-
bral cortex, dorsal raphe nucleus, and others [50, 51, 55–
58]. Moreover, similar to the harmaline-induced tremor, the
tremor induced by acetylcholesterase inhibitors was re-
duced by inhibition of serotonin synthesis by PCPA or
blockade of 5-HT2A/2C receptors [55, 56]. All the above
data together with those of the present study may suggest
that an increased serotonergic transmission in several brain
structures, including the basal ganglia and frontal cortex,
may be a common mechanism involved in different forms
of tremor.
The question arises how the lesion of noradrenergic
innervations of the cerebellar cortex modulated serotonergic
and noradrenergic transmission in distant structures. Purkinje
cells, which are innervated by noradrenergic terminals arising
from the locus coeruleus [14], are the main efferent neurons
of the cerebellar cortex and extend their projections to the
subcortical cerebellar nuclei [59]. These nuclei, in turn, send
their fibers to the thalamus and via the latter structure may
functionally control the striatum and cerebral cortex [60, 61].
On the other hand, it could be expected that the intra-
cerebellar injection of a noradrenergic toxin retrogradely
destroyed the coeruleo-cerebellar pathway which might
induce a compensatory activation of other projections of the
locus coeruleus to the striatum, cerebral cortex, and raphe
nuclei [62–64] and in this way may interact with serotonergic
neurons at the levels of these structures. Precise neuronal
278 Cerebellum (2011) 10:267–280mechanisms involved in these interactions and their relation
to the harmaline-induced tremor may be, however, very
c o m p l e xa n dn e e d st ob ee v a l u a t e di nt h ef u t u r e .
Summing up, the present study shows that degeneration
of noradrenergic terminals in the cerebellar cortex enhances
the harmaline-induced tremor and modulates noradrenergic
and serotonergic transmissions in the basal ganglia and
frontal cortex. The role of these alterations in different
forms of tremor in humans has to be established in the
future.
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